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ABSTRACT
Objective: The objective of this study was to determine the correlation between cluster of differentiation 4 (CD4) counts, human immunodeficiency 
virus (HIV) clinical stages, and hemoglobin (Hb) level among HIV-infected patients with anemia.
Methods: A cross-sectional study was conducted in November 2017 at Merpati Clinic of Wangaya Hospital, Denpasar, Bali, Indonesia. We selected 79 
HIV patients with anemia to participate in our study. We grouped CD4 counts into two categories: <200 cells/µL and ≥200 cells/µL, and we classified 
the HIV clinical stages into HIV and acquired immunodeficiency syndrome (AIDS).
Results: About 55.7% (44) of men and 44.3% (35) of women were participated in this study. As many as, 91.1% (72) of participants were AIDS 
patients. The mean Hb was 8.77 g/dl with SD 1.79 g/dl. 81% (64) of study participants were suffered from anemia on chronic disease or inflammatory 
anemia, and 19% (15) of study participants were suffered from iron deficiency anemia. The median for CD4 counts was 94 cells/μL (3–309 cells/µL) 
with as many as 78.5% (62) of participants were found to have low CD4 counts (<200 cells/µL). Spearman analysis revealed a positive correlation 
between CD4 counts and Hb level (r=0.427, p<0.001). Independent sample t-test analysis found a correlation between the HIV clinical stages and Hb 
level. There was a difference between the mean of Hb level in each stage with the average difference of 0.8 g/dl (95% confidence interval 0.04–1.6; 
p<0.04).
Conclusions: There is a correlation between CD4 counts, HIV clinical stages, and Hb level among HIV patients with anemia.
Keywords: Human immunodeficiency virus clinical stages, Cluster differentiation 4 counts, Anemia.
INTRODUCTION
Anemia is the most common hematologic disorder associated with 
human immunodeficiency virus (HIV) infection affecting 60–80% of 
patients in the late stages of HIV at various cluster of differentiation 4 
(CD4) levels and with various causes [1-3].
The pathophysiology of HIV-related anemia involves three basic 
mechanisms, which are decreased red blood cell production, increased 
red blood cell destruction, and ineffective production of red blood cells. 
Anemia can also be a result of nutritional deficiency, most commonly iron, 
folic acid, and Vitamin B12. Vitamin B12 deficiency is associated with 
malabsorption in the ileum or due to gastric pathological processes caused 
by infections affecting the gastric mucosa in patients with HIV [4-6].
Although anemia can occur in any stages of HIV infection, its severity 
positively correlates with progression of the disease and mortality [7].
Owiredu et al. reported that highly active antiretroviral therapy can 
increase B12 serum level; however, they do not describe symptoms 
associated with B12 deficiency such as macroscopic anemia and 
neuropathy. Anemia independently decreases the survival of the 
patient (HR 2.6, 95% confidence interval [CI] 1.9–3.4), improves 
disease progression, and increases mortality in HIV-infected 
individuals [6,8-29].
The incidence of anemia increases annually with the progression of 
the disease, affecting 3% of all asymptomatic HIV infection patients, 
12% of asymptomatic patients with CD4<200/μL, and 37% of patients 
with acquired immunodeficiency syndrome (AIDS). The risk of anemia 
increases in African-American race, older age, low body mass index, 
history of pneumonia, oral candidiasis, history of fever, use of zidovudine 
(ZDV), low CD4 cell counts, and high HIV-1 RNA levels in plasma. ZDV 
was reported as a cause of hematological disorders, especially, anemia 
at weeks 4–12 of ZDV initiation [11-21,30-47].
The causes of anemia in HIV patients are multifactorial, such as the HIV 
itself, opportunistic infection, immune mechanisms, malignancies, and 
drugs. Nutritional anemia in HIV patients due to an inadequate diet 
intake and malabsorption. High viremia, decreased CD4 counts, and 
severity of anemia (lower hemoglobin [Hb] levels) are associated with 
increased morbidity and mortality in HIV-infected patients [3,7,8,11,14].
This study was to evaluate the correlation of anemia to CD4 counts 
and HIV clinical stages in HIV patients were visited to Merpati Clinic, 
Wangaya hospital, Denpasar, Bali, Indonesia.
METHODS
A cross-sectional study was conducted in November 2017 at Merpati 
Clinic of Wangaya Hospital, Denpasar, Bali. Ethical clearance was 
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obtained No: 05/RSUDW/Litbang/2017 from the local ethical 
committees. We collected data from a patient who visited Merpati Clinic 
and completed at least 1 year follow-up from the ethical clearance 
granted date.
Research purposes
This study aimed to determine the correlations between CD4 counts, 
HIV clinical stages, and Hb level among HIV patients with anemia.
Research design
A cross-sectional study was conducted at Merpati Clinic, Wangaya 
Hospital, Denpasar, Bali-Indonesia. We recruited 79 HIV patients with 
various stages of anemia.
Population and duration of the study
The study participants were HIV patient with various stages of anemia 
visiting the outpatient services of Merpati Clinic, Wangaya Hospital, 
Denpasar, Bali, Indonesia. The participants were aged between 18 and 
65 years old. The study was conducted in November 2017.
Sample size
Using a consecutive sampling technique, we included a total of 
79 patients. Every patient who met the criteria was selected until we 
reached the desired sample size. The inclusion criteria included HIV 
patients with anemia, aged over 18 years old. We excluded pregnant 
and lactating women, patients with chronic renal impairment, and 
patients with thalassemia.
Variables and data sources
Our study variables included CD4 counts, HIV clinical stages, and Hb 
levels. We also collected data on social demographic characteristics 
such as age, sex, and other laboratory parameters.
Data analysis
We used a structured questionnaire to obtain data on sociodemographic 
characteristics. The HIV clinical stages of all participants were 
determined using the World Health Organization (WHO) guideline and 
were grouped as clinical HIV and advanced clinical form of AIDS.
CD4 parameters were measured following the recommended guideline 
and were grouped into two categories: CD4 ≥200 cells/µL and 
<200 cells/µL. Hb level was obtained from routine hematology test 
and was grouped into four groups: Mild anemia (Hb: 10–11.9 g/dl), 
moderate anemia (Hb: 9.9–7 g/dl), severe anemia (Hb: 6.9–4 g/dl), and 
very severe anemia (Hb: 4 g/dl).
We displayed the average and standard deviation for all numerical 
or continuous variables. However, we used median and interquartile 
range for all data that were not normally distributed. Categorical 
data were presented in relative frequency (number and percent). We 
performed the non-parametric analysis to determine correlations of 
each independent variable with Hb level. We used the precision value of 
95% (p<0.05). All data analysis was performed using SPSS software for 
Windows version 24.0.
RESULTS
A total of 79 individuals with HIV infection in various stages of anemia 
were participated in this study. The sociodemographic characteristics 
are presented in Table 2.
The WHO defines anemia as Hb level under 13 g/dl for men and 
under 12 g/dl for women. For the purpose of this study, we used the 
classification as depicted in Table 1 [6].
The age data were not normally distributed when tested using the 
Kolmogorov–Smirnov test. The median of age data for all participants 
was 37 years old, with the youngest of 20 years old and the oldest of 
75 years old. The body mass index was normally distributed with a 
mean of 18.65 kg/m2 (SD±2.86 kg/m2). The overall CD4 counts of the 
participants were not normally distributed. The median of CD4 counts 
of all participants was 94 cells/µL with the lowest of 3 cells/µL and the 
Table 1: Staging of anemia severity [6]





Table 2: The sociodemographic characteristics of participants (sex, 
education, marital status, anemia morphology, anemia severity, HIV 






Non-formal education 2 (2.5)
Elementary school 6 (7.6)
Junior high school 19 (24.1)













Very severe 2 (2.5)










Without opportunistic infection 8 (10.1)
With opportunistic infection 71 (89.9)
n=79, Values are numbers or numbers (%). CD4: Cluster of differentiation 
4, HIV: Human immunodeficieny virus, AIDS: Acquired immunodeficieny 
syndrome, ACD: Anemia of chronic disease, IDA: Iron deficiency anemia
Table 3: Participants’ characteristic (age, height, weight, BMI, 
and hematologic data)
Characteristic Mean±SD/median (minimum–maximum)
Age (year) 37 (20–75)
Height (cm) 160 (148–185)




SI (mg/L) 42 (7–187)
TIBC (mg/mL) 104 (37–602)
Ferritin (µg/ml) 425 (16–678)
Lymphocyte (%) 14.1 (1.7–41.4)
CD4 counts (cells/µL) 94 (3–309)
n=79, Values are numbers or numbers (range). Data are expressed as mean±SD. 
SD: Standard deviation, Hb: Hemoglobin, BMI: Body mass index, CD4: Cluster of 
differentiation 4, SI: Serum iron, TIBC: Total iron binding capacity
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highest of 309 cells/μL. The Hb levels of all participants were normally 
distributed with mean values of 8.77 g/dl (SD±1.79 g/dl (Table 3).
Correlation between CD4 counts and Hb levels
Due to the CD4 counts, data were not normally distributed, and we 
performed a non-parametric correlation (Spearman) analysis to 
determine the correlation between CD4 counts and Hb level (Table 4).
The relationship between clinical stage and Hb levels
Independent sample t-test was performed to assess the relationship 
between HIV clinical stages and Hb levels (Table 5).
DISCUSSION
Correlation between CD4 counts and Hb levels
Anemia is one of the most common abnormalities seen in HIV. The 
severity of anemia correlates with the late clinical HIV stage and 
low CD4 counts. An increased number of viruses along with the 
development of HIV was followed by the release of inflammatory 
cytokines such as tumor necrosis factor (TNF), interleukin-1, and 
interferon gamma. The cytokines have been shown to inhibit red cell 
production (erythropoiesis) and myelosuppression. TNF levels were 
found to be consistently elevated in HIV infection, and this condition 
is correlated with viral load. As HIV disease progresses, the severity of 
anemia also increases [12,17,23,27,31-41].
This study found a moderate positive correlation between CD4 counts 
and Hb level (r=0.427; p<0.001).
Obirikorang and Yeboah, 2009, in a prospective case–control study 
involving 228 individuals with HIV in Ghana, also found a positive 
correlation between Hb levels and CD4 counts (r=0.1755; p<0.0001) [22].
Hb is an easy and cheap parameter that can be used to predict morbidity 
and mortality of a progression of HIV infection. Hb monitoring can alert 
clinicians regarding anemia conditions of HIV patients and to determine 
anemia treatments required or not.
Similar studies by Paras et al., 2017, found that low CD4 counts were 
significantly associated with anemia (p=0.0001) [23,29,30,42].
Moore et al., 1998, found that anemia therapy using erythropoietin 
was associated with improved prognosis allowing a long-term 
administration of ZDV.
A cross-sectional study of Hb measurements has consistently shown to 
play an important role in the basic management of HIV disease in West 
Africa [24,25,28,43].
However, Alavi et al., 2009, found that there was no correlation 
between CD4 counts and Hb levels (r=0.451; p=0.056). This 
finding might be confounded by malnutrition and various 
socioeconomic factors, including a history living in prison and 
the use of injecting narcotics resulting in chronic anemia and low 
Hb levels. Moreover, three-quarters of the participants in their 
study were injecting drug users that misappropriately represent 
the true HIV situation [26,44,45].
The clinical staging of HIV infection with Hb levels
HIV infection is caused a gradual loss of CD4 counts. Loss of CD4 
counts and systemic immune activation are the major hallmarks of 
HIV infection. Systemic immune activation is characterized by massive 
production of pro-inflammatory cytokines [14,17,19,23].
This study revealed a significant relationship between HIV clinical 
stages and Hb levels. The mean Hb level among HIV stage was 
9.5±0.8 g/dl and the mean Hb among AIDS stage was lower: 8.7±1.8 g/
dl. An average difference between HIV and AIDS patients was 0.8 g/dl 
(95% CI 0.04–1.64; p<0.04). This finding indicates that the severity of 
anemia increases with the progression of the HIV clinical stages.
Similar studies in India by Mathews et al., 2013, with 187 participants 
found a higher proportion of anemia among patients in AIDS than pre-
AIDS clinical stages [27].
Alavi  et al., 2009, in a cross-sectional study conducted in India with 
306 participants, aimed to examine the incidence of anemia and its 
association with the WHO-based clinical staging and found that the 
proportion of anemia was higher among patients with HIV stage 
4 (33.3%) when compared with stage 1 (1.2%). They also found that the 
severity of anemia increases with HIV clinical stages (p=0.0001) [23].
CONCLUSIONS
Anemia is a common problem among HIV-infected patients, as a result 
of chronic inflammation or antiretroviral therapy. This study shows that 
the CD4 counts and HIV clinical stages correlate with Hb level among 
HIV patients with anemia. The severity of anemia correlates with low 
CD4 counts and advance HIV clinical stage.
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Table 4: Correlation between CD4 counts and Hb levels
Variables Mean±SD (minimum–maximum) r p-value
CD4 counts 94 (3–309) cell/µL 0.427 <0.001**
Hb levels 8.8±1.8 g/dl
n=79, Values are numbers or numbers (range). Data are expressed as mean±SD. 
SD: Standard deviation, p<0.05 is statistically significant, CD4: Cluster of 
differentiation 4. In the data analysis, there was a significant moderate 
positive correlation (r=0.472) between CD4 counts and Hb level (p<0.001), 
Hb: Hemoglobin
Table 5: The relationship between HIV clinical stages and Hb 
levels
Variable HIV clinical stages
HIV (n=7) AIDS (n=72)
Hb 9.5±0.8 8.7±1.8
n=79, Data are expressed as mean±SD. SD: Standard deviation, HIV: Human 
immunodeficieny virus, AIDS: Acquired immunodeficieny syndrome, Mean 
of Hb levels among participants with HIV was 9.5±0.8 and in participants 
with AIDS 8.7±1.8. The data analysis found a statistically significant mean 
difference of Hb level among HIV and AIDS patients (95% CI 0.04–1.64; p<0.04), 
Hb: Hemoglobin
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